The article discusses whether Tempus AI stock is a good investment following its CEO's sale of 250,000 shares.

Tempus AI has acquired Personalis, a cancer-monitoring firm, for $1.5 billion in a deal focused on precision oncology. This acquisition aims to enhance Tempus AI's capabilities in cancer diagnostics and treatment.

Freedom Capital has begun its coverage of Tempus AI, Inc. (TEM), a significant development for the artificial intelligence company.

Tempus AI stock is reportedly facing a make-or-break moment after experiencing a recent pullback, indicating a crucial period for its market performance.

Despite market fluctuations, Redditors continue to express confidence that Tempus AI (TEM) retains the potential for a tenfold increase in its stock value.

H.C. Wainwright has reiterated its Buy rating on Tempus AI, citing the company's strong revenue growth as a key factor in its positive outlook.

An analysis suggests that the currently undervalued Tempus AI stock could present a significant opportunity for traders.

An article evaluates whether Tempus AI (TEM) is a top investment choice among AI healthcare stocks, providing analysis for potential buyers.

Tempus AI, Inc. has released its earnings summary for the first quarter of 2026, detailing its financial performance.

Reports indicate Nancy Pelosi's interest in specific companies, including AI-powered medicine firm Tempus AI Inc. and investment company AllianceBernstein Holding L.P. These highlight her recent stock preferences.

Tempus AI Inc. (TEM) is being recommended as a buy, with analysts highlighting the company's focus on healthcare opportunities.

A summary of Tempus AI, Inc.'s fourth-quarter 2025 earnings call has been released.

Tempus AI stock saw an increase in value, with investors closely watching developments before next week's earnings announcement.

First Internet projects $2.35-$2.45 full-year EPS and targets a 2.75%-2.80% FTE NIM by Q4 2026. Tempus aims for $1.595B-$1.605B in 2026 revenue, with a projected $400M uplift by 2028 from xT CDx and xF.

Tempus AI has announced its acquisition of Personalis, a cancer-monitoring firm, for $1.5 billion. This strategic move aims to expand Tempus AI's growth in MRD (minimal residual disease) testing.

Tempus AI has introduced a new agentic platform designed to accelerate oncology research, leveraging advanced technology to enhance scientific discovery in cancer treatment.

Tempus AI (TEM) is listed among AI stocks priced under $30 that are currently experiencing high short interest from investors.

Tempus AI, Inc. (TEM) has announced the opening of an open-source digital pathology consortium.

Tempus AI (TEM) has launched the ArteraAI Prostate Test, marking it as the first externally developed digital pathology algorithm to be introduced by the company.

Cathie Wood's ARK Invest has updated its weekly portfolio, including new buys in Cerebras and Tempus AI, while selling shares in AMD and TSM.

APi Group's subsidiary has priced a $500 million notes offering, and Tempus AI has priced an upsized $400 million offering. These financial moves aim to raise capital for the respective companies.

Tempus AI (TEM) has announced a partnership with Keck Medicine of USC to integrate artificial intelligence across its healthcare network, aiming to enhance medical operations.

Gilead (GILD) and Tempus AI (TEM) have announced an expansion of their multi-year collaboration in oncology research and development.

An article examines whether Tempus AI (TEM) stands out as the premier AI healthcare stock within Cathie Wood's investment portfolio.

Merck has announced a collaboration with Tempus AI to advance precision oncology initiatives, focusing on leveraging AI for cancer treatment and research.

Tempus AI has outlined a revenue target of $1.59 billion for 2026, projecting 25% growth driven by its accelerating diagnostics and data businesses.

Investors interested in Tempus AI stock are advised to mark their calendars for July 30, indicating a significant upcoming event for the company's shares.

Tempus AI announced its plan to acquire Personalis in a $1.5 billion deal, aiming to expand its MRD cancer testing capabilities.

Tempus AI (TEM) is highlighted for its innovative application of artificial intelligence to drive advancements in precision medicine.

An analysis explores whether Tempus AI, Inc. (TEM) is considered a leading stock for investment in the AI drug discovery sector by hedge funds.

According to analysts, Tempus AI (TEM) stands out as one of the top healthcare mid-cap AI stocks, highlighting its strong position in the intersection of healthcare and artificial intelligence.

The Aristotle Core Equity Fund has placed a bet on Tempus AI (TEM), a healthcare technology company, indicating confidence in its future prospects.

Tempus AI is projecting revenues between $1.59 billion and $1.6 billion and approximately $65 million in adjusted EBITDA by 2026, supported by its collaboration with Merck.

This article analyzes Tempus AI, Inc. (TEM) stock, providing insights into whether it represents a favorable investment opportunity.

Jim Cramer shared his perspective on Tempus AI, advising investors to hold onto some of the stock but not all, describing it as a 'decent spec'.

Tempus AI, Inc. has announced a strategic deal with Merck to accelerate AI-driven precision medicine initiatives.

Tempus AI announced an 83% revenue growth but fell short of its full-year profitability target, as detailed in its latest financial report.